Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide Combined With VDDT in Relapsed/Refractory DLBCL
NCT02733380Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- May 2016
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Henan Cancer Hospital. Primary endpoints: Objective Response Rate at 1 year, Adverse Events at 1 year and 2 more. Status: unknown.
02
Drugs
tucidinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02733380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733380.